Point72 Hong Kong’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Point72 Hong Kong’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-459	Closed	-$14K	–	2538
2022 Q2	$14K	Buy	+459	New	+$13.7K	﹤0.01%	1632
2021 Q4	–	Sell	-414	Closed	-$42K	–	2537
2021 Q3	$42K	Buy	414 +37	+10%	+$4.34K	﹤0.01%	1567
2021 Q2	$53K	Sell	377 -1,923	-84%	-$217K	﹤0.01%	1461
2021 Q1	$229K	Buy	2,300 +687	+43%	+$80.1K	0.01%	1023
2020 Q4	$199K	Buy	+1,613	New	+$212K	0.01%	940
2020 Q3	–	Sell	-654	Closed	-$102K	–	1624
2020 Q2	$102K	Buy	+654	New	+$99.4K	0.01%	621
2019 Q3	–	Sell	-168	Closed	-$16K	–	1435
2019 Q2	$16K	Buy	168 +143	+572%	+$12.3K	﹤0.01%	813
2019 Q1	$2K	Buy	+25	New	+$2.08K	﹤0.01%	908
2018 Q4	–	Sell	-458	Closed	-$37K	–	1283
2018 Q3	$37K	Sell	458 -135	-23%	-$9.51K	0.01%	511
2018 Q2	$21K	Buy	+593	New	+$18.1K	0.01%	577

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Hong Kong's RETA Position: Q3 2022 in Review

Point72 Hong Kong sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 459 shares — an estimated $14K sold.

Point72 Hong Kong first reported a position in RETA in Q2 2018 and held it in 10 quarters. The position peaked at $229K in Q1 2021. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

Point72 Hong Kong reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 459 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $14K.
Point72 Hong Kong first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 10 quarters.
Point72 Hong Kong's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $229K in Q1 2021.
159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.